R
10.13
-0.05 (-0.49%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Replimune Group, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.4
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.38 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.51% |
| 机构持股比例 | 107.49% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Fcpm Iii Services B.V. | 31 Mar 2025 | 3,909,696 |
| Sofinnova Investments, Inc. | 31 Mar 2025 | 2,479,939 |
| Boxer Capital Management, Llc | 31 Mar 2025 | 1,796,341 |
| 52周波幅 | ||
| 中 | 22.00 (117.18%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 02 Jun 2025 | 22.00 (117.18%) | 购买 | 9.57 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合